Integrated Advisors Network LLC Trims Stock Holdings in Elevance Health, Inc. $ELV

Integrated Advisors Network LLC reduced its holdings in shares of Elevance Health, Inc. (NYSE:ELV) by 26.3% in the first quarter, according to its most recent filing with the SEC. The fund owned 3,651 shares of the company’s stock after selling 1,304 shares during the period. Integrated Advisors Network LLC’s holdings in Elevance Health were worth $1,069,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the business. Norges Bank purchased a new stake in Elevance Health in the fourth quarter worth $1,058,165,000. Wellington Management Group LLP boosted its stake in shares of Elevance Health by 25.2% during the fourth quarter. Wellington Management Group LLP now owns 8,289,976 shares of the company’s stock valued at $2,906,051,000 after purchasing an additional 1,668,679 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in shares of Elevance Health by 27.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,446,185 shares of the company’s stock valued at $2,610,261,000 after purchasing an additional 1,607,274 shares during the period. Invesco Ltd. grew its holdings in shares of Elevance Health by 50.3% in the fourth quarter. Invesco Ltd. now owns 3,903,878 shares of the company’s stock worth $1,368,505,000 after purchasing an additional 1,306,390 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in shares of Elevance Health by 79.3% in the fourth quarter. Bank of New York Mellon Corp now owns 2,408,704 shares of the company’s stock worth $844,371,000 after purchasing an additional 1,065,065 shares during the last quarter. Institutional investors own 89.24% of the company’s stock.

Insider Transactions at Elevance Health

In other Elevance Health news, Director Robert L. Dixon, Jr. sold 151 shares of the stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $401.77, for a total value of $60,667.27. Following the completion of the sale, the director directly owned 10,734 shares in the company, valued at approximately $4,312,599.18. This trade represents a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.34% of the stock is owned by corporate insiders.

Elevance Health Trading Down 0.7%

NYSE:ELV opened at $415.99 on Thursday. The stock has a market capitalization of $90.34 billion, a price-to-earnings ratio of 17.69, a PEG ratio of 2.38 and a beta of 0.67. Elevance Health, Inc. has a 52 week low of $273.71 and a 52 week high of $427.19. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.70. The firm has a 50 day moving average of $395.21 and a 200 day moving average of $352.48.

Elevance Health (NYSE:ELV) last released its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.74 by $1.84. The business had revenue of $49.49 billion for the quarter, compared to analyst estimates of $48.21 billion. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The business’s revenue for the quarter was up 1.5% on a year-over-year basis. During the same period in the previous year, the company earned $11.97 earnings per share. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, sell-side analysts anticipate that Elevance Health, Inc. will post 26.86 earnings per share for the current fiscal year.

Elevance Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 25th. Investors of record on Wednesday, June 10th were paid a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a yield of 1.7%. The ex-dividend date was Wednesday, June 10th. Elevance Health’s payout ratio is 29.26%.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ELV. Raymond James Financial set a $450.00 price objective on shares of Elevance Health in a report on Tuesday. Robert W. Baird upped their target price on shares of Elevance Health from $317.00 to $331.00 and gave the stock a “neutral” rating in a research note on Thursday, April 23rd. Citigroup raised shares of Elevance Health to a “buy” rating in a research note on Wednesday, April 29th. Cantor Fitzgerald boosted their price target on Elevance Health from $400.00 to $450.00 and gave the company an “overweight” rating in a report on Tuesday. Finally, Leerink Partners set a $364.00 price objective on Elevance Health in a research note on Thursday, April 23rd. Fifteen equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $422.10.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.